tbuckley/cabot-search huggingface dataset:
AT-14 * LONG-TERM PROGRESSION-FREE SURVIVAL OF RECURRENT GLIOBLASTOMA MULTIFORME TREATED WITH A COMBINATION OF TARGETED AGENTS: A CASE REPORT
Authors: S. Burzynski, G. Burzynski
Journal: Neuro-Oncology (2014)

The introduction of targeted therapy is among the most important advances in oncology, but the use of single agents did not translate into a meaningful increase of survival in glioblastoma multiforme (GBM). The availability of molecular analysis of tumor specimens, increased the chances of designing a treatment plan based on pathway inhibition, which may provide a better outcome. This case report illustrates the successful treatment of recurrent GBM by using a combination of phenylbutyrate (PB), bevacizumab (BVZ), erlotinib, rapamycin, and temozolomide (TMZ). A 53-year-old male underwent a subtotal resection of a large GBM (8 x 5.5 cm) involving the right temporal, occipital and parietal lobes and corpus callosum. He was followed with standard radiation therapy (RT) with concurrent TMZ, but after two weeks from completion of RT, he developed recurrence and underwent a second resection. Six weeks later, he began treatment at the Burzynski Clinic with PB, BVZ, erlotinib, rapamycin, and TMZ. He was given 6 cycles of TMZ, 8 cycles of BVZ and 17 months of erlotinib and rapamycin. Standard doses of the drugs had been used except that rapamycin was given at 0.01 mg/kg/d and PB at 0.15 g/kg/d. After one year, there was a 50% reduction in the dose of erlotinib. The baseline MRI revealed a 5.2 x 4.3 cm recurrent tumor, which was no longer visible after six weeks of treatment. The follow-up MRIs at quarterly intervals and PET/CT scan did not show tumor recurrence. The treatment was associated with minor adverse events including grade 2 skin rash and diarrhea, which resolved after a dosage modification. The patient is surviving in excellent condition and his overall survival and progression-free survival are over two years. His treatment plan was designed based on the data from molecular profiling.
Systemic Microdystrophin Gene Delivery Improves Skeletal Muscle Structure and Function in Old Dystrophic mdx Mice
Authors: Paul Gregorevic, Michael J Blankinship, James M Allen, Jeffrey S Chamberlain
Journal: Molecular Therapy (2008)

Restoring dystrophin expression in the muscles of patients with Duchenne muscular dystrophy (DMD) may halt or reverse the degenerative wasting and weakness that causes premature death. However, the therapeutic efficacy of an intervention may be limited by the extent of disease progression prior to treatment. In this study, we considered the potential for ameliorating the pathology in a mouse model of advanced-stage muscular dystrophy by systemic administration of recombinant adeno-associated viral (rAAV6) vectors encoding a microdystrophin expression construct. The treatment of 20-month-old mdx mice restored body-wide expression of a dystrophin-based protein in striated musculature. In aged mice that received treatment, the resultant dystrophin expression was associated with improved hindlimb and respiratory muscle morphology and function, concomitant with reduced muscle fiber degeneration. The findings demonstrate that an established dystrophic state remains amenable to improvement with appropriate intervention and, by some measures, may even achieve benefits similar to those observed with intervention early in disease progression. The capacity to ameliorate the pathology in an animal model of advanced-stage muscular dystrophy suggests that interventions ultimately proven to exert a therapeutic effect in young patients may offer benefits to older patients or those with advanced conditions of progressive muscular dystrophy. Restoring dystrophin expression in the muscles of patients with Duchenne muscular dystrophy (DMD) may halt or reverse the degenerative wasting and weakness that causes premature death. However, the therapeutic efficacy of an intervention may be limited by the extent of disease progression prior to treatment. In this study, we considered the potential for ameliorating the pathology in a mouse model of advanced-stage muscular dystrophy by systemic administration of recombinant adeno-associated viral (rAAV6) vectors encoding a microdystrophin expression construct. The treatment of 20-month-old mdx mice restored body-wide expression of a dystrophin-based protein in striated musculature. In aged mice that received treatment, the resultant dystrophin expression was associated with improved hindlimb and respiratory muscle morphology and function, concomitant with reduced muscle fiber degeneration. The findings demonstrate that an established dystrophic state remains amenable to improvement with appropriate intervention and, by some measures, may even achieve benefits similar to those observed with intervention early in disease progression. The capacity to ameliorate the pathology in an animal model of advanced-stage muscular dystrophy suggests that interventions ultimately proven to exert a therapeutic effect in young patients may offer benefits to older patients or those with advanced conditions of progressive muscular dystrophy.
The Appropriateness of Tympanostomy Tubes for Children
Authors: Kenneth M. Grundfast
Journal: JAMA (1995)

<h3>To the Editor.</h3> —The report by Dr Kleinman and colleagues<sup>1</sup>was as inflammatory as it was enlightening. Despite the provocative title, the study did not assess the efficacy of one treatment compared with other alternatives. Rather, the study simply measured the degree to which a recommendation for insertion of tympanostomy tubes met a set of criteria established by VHS, a for-profit corporation. Kleinman et al have not demonstrated that watchful waiting or administration of antimicrobial agents in the treatment of otitis media are better choices than insertion of tubes. We have no idea what happened to the patients in the study sample. The outcomes desired were not specified and no follow-up data were provided. This being the case, we should recognize that what we have feared for so long (ie, the influence of a growing group of detached number crunchers on the practice of medicine) is not in the
A New Oral Isotopic Test of Calcium Absorption *
Authors: Louis V. Avioli, Joseph E. McDonald, Richard A. Singer, Philip H. Henneman, Sook Won Lee, Erika Hessman
Journal: Journal of Clinical Investigation (1965)

Abnormal absorption of dietary calcium has been recognized for many years in intestinal dis- eases, sarcoidosis (1), idiopathic hypercalciuria (2), hypoparathyroidism (3, 4), hyperparathyroidism (5-7), and more recently in calcinosis universalis (8).Understanding of calcium ab- sorption in the past has been limited by the re- quirement of 18 to 20 days of metabolic balance procedures; interpretation has been limited by the paucity of data in normal subjects.This paper describes a safe and simple 4-hour isotopic test of calcium absorption that has been evaluated statistically in 21 normal subjects and in 31 pa- tients with disorders known to alter calcium absorption. MethodsTwenty-one normal subjects (average age, 36; range, 21 to 65 years) and 31 patients (average age, 44; range, 14 to 73 years) with disorders likely to alter calcium absorption were studied.The latter group consisted of 14 patients with disorders characterized by decreased intestinal absorption (hypoparathyroidism, celiac dis- ease, postsurgical malabsorption, regional ileitis, and calcific pancreatitis with insufficiency) and 17 patients with disorders characterized by increased calcium ab- sorption (hyperparathyroidism, sarcoidosis, idiopathic hypercalciuria, and calcinosis universalis).The diagnoses of intestinal malabsorption were established by the pres- ence of steatorrhea, diminished D-xylose absorption, ab- normal small bowel series, and salutary response to a gluten-free diet in the patients with celiac disease.The clinical diagnoses of hyperparathyroidism and sarcoidosis were confirmed histopathologically.One patient (A.D.) with tetany, hypocalcemia, and hyperphosphatemia was found to have idiopathic hypoparathyroidism.Patients with normal serum calcium, decreased serum phos- *
Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection
Authors: M. Willems, K. Munte, J.M. Vrolijk, J.C. den Hollander, M. Bohm, M.H. Kemmeren, R.A. de Man, J.T. Brouwer
Journal: British Journal of Dermatology (2003)

Summary Many types of skin disorders concomitantly occur with hepatitis C virus infection. These skin lesions may be induced or worsened during antiviral therapy with interferon-alpha (IFN). To our knowledge, hyperpigmentation of the skin—and especially of the tongue—has not been reported so far. We describe two dark-skinned patients who developed hyperpigmented skin and tongue lesions during combination therapy with IFN and ribavirin. Immunohistochemical analysis of tongue biopsies confirmed the suspicion of melanin deposits in these areas of hyperpigmentation. We hypothesize that during interferon therapy, melanocytes may produce more melanin pigment in the presence of α-melanocyte stimulating hormone and sufficient amounts of tyrosine, leading to melanin deposits and clinical hyperpigmentation.
Measuring Mental Health in Child Soldiers
Authors: Alexander C. Tsai
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7. Diabetes Care 2013;36:908–913
Authors: Mohammed I. Hawa, Hubert Kolb, Nanette Schloot, Huriya Beyan, Stavroula A. Paschou, Raffaella Buzzetti, Didac Mauricio, Alberto De Leiva, Knud Yderstraede, Henning Beck-Neilsen, Jaakko Tuomilehto, Cinzia Sarti, Charles Thivolet, David Hadden, Steven Hunter, Guntram Schernthaner, Werner A. Scherbaum, Rhys Williams, Sinead Brophy, Paolo Pozzilli, Richard David Leslie
Journal: Diabetes Care (2014)

In the print version of the article cited above, the affiliation for Didac Mauricio and Alberto De …
David Wilfried Levy
Authors: A. Banerjee
Journal: BMJ (2008)

Qualifying in South Africa, David Wilfried Levy spent his earlier professional years working at Groote Schuur Hospital, Cape Town, and later as a consultant physician at Port Elizabeth, where he developed his lifelong interest in renal disorders. He set up a peritoneal dialysis service in the surrounding community, leading a dedicated team of experts. David left South Africa in 1978, along with many other liberals, …
Ventricular arrhythmias caused by prenylamine.
Authors: R Puritz, M A Henderson, S N Baker, D A Chamberlain
Journal: BMJ (1977)

active cellular reuptake of released noradrenaline,4 and this probably contributes to its antagonism of antihypertensive agents and to its hypertensive interaction with monoamine oxidase inhibitors.Although tricyclic antidepressants may theoretically potentiate the pressor effect of noradrenaline derived from levodopa, the combination of amitriptyline and levodopa is apparently safe,4 and there are no reports of hypertensive crises in patients on Sinemet and amitriptyline.Furthermore, hypertensive responses to other combinations of Sinemet, amitriptyline, and metoclopramide have not previously been described.These three agents are not uncommonly used together to treat patients with Parkinson's disease, and prescribers should be aware of the possibility of a potentially dangerous reaction to such treatment.
A Different View of Smallpox and Vaccination
Authors: Thomas Mack
Journal: New England Journal of Medicine (2003)

According to federal,1 academic,2 and lay3 observers, smallpox might be used as a weapon of terrorism. Variola virus is presumed to be available,4 and a terrorist could introduce it, leading to secondary spread and deaths. Current policy is to promote vaccination, initally to 1/2 million hospital-selected health care providers5 and subsequently to as many as 10 million others.6 This policy should be compared with alternatives in the light of the likely outcome of an introduction of variola virus into this country. Three decades ago, I was among those who investigated the dynamics of smallpox transmission by direct observation in Pakistan. . . .
PLASMA ANGIOTENSINASE ACTIVITY IN PATIENTS WITH HYPERTENSION AND EDEMA*
Authors: Roger B. Hickler, David P. Lauler, George W. Thorn
Journal: Journal of Clinical Investigation (1963)

An abnormal metabolism of angiotensin II in essential hypertension has been suggested by several studies.Wood (1) reported that the venous blood of hypertensive patients showed a decreased capacity to inactivate an in vitro admixture with synthetic angiotensin' as judged by the pressor response on reinfusion into the hypertensive donors.Wolf and associates reported a prolonged radiochemical half-life of I131-labeled angiotensin in hypertensive patients after intravenous administration (2), but found a shortened radiochemical half-life in a purely in vitro system (3).Klaus (4) described a system in which the measurement of the amount of valine freed from synthetic valyl-5-angiotensin II after an in vitro admixture with plasma was equated to angiotensinase activity and reported no significant difference between hypertensive and normotensive plasma.Thus, in the in vitro system employed, there has been suggested an increase, a decrease, and no change in the angiotensinase activity of the hypertensive plasma.2Using the pressure response of the subject on reinfusion of an in vitro admixture leaves the difficult problem of controlling differ- ences in vascular tone and reactivity between hypertensive and normotensive individuals.
Retention of Enrollees Following a Cancer Diagnosis Within Health Maintenance Organizations in the Cancer Research Network
Authors: T. S. Field, J. Cernieux, D. Buist, A. Geiger, L. Lamerato, G. Hart, D. Bachman, R. Krajenta, S. Greene, M. C. Hornbrook, G. Ansell, L. Herrinton, G. Reed
Journal: JNCI Journal of the National Cancer Institute (2004)

Population laboratories with complete clinical information on episodes of care are needed to support research on the quality of care delivered to cancer patients. Data resources within the Cancer Research Network (CRN) may overcome many of the limitations of existing cancer databases, but their potential clinical value depends on the stability of the enrolled population. To assess this issue, we studied the retention rates among survivors of the 132 580 patients diagnosed with cancer from January 1, 1993, through December 31, 1998, who were enrolled at five health maintenance organization sites participating in the CRN. Enrollees were followed from cancer diagnosis through death, disenrollment, or the end of follow-up (i.e., December 31, 1999). The retention rate among survivors for all cancers combined at 1 and 5 years after cancer diagnosis was 96.0% (95% confidence interval [CI] = 95.9% to 96.1%) and 83.9% (95% CI = 83.4% to 84.3%), respectively. The proportion of enrollees diagnosed with cancer who remained enrolled and available for evaluation suggests that the CRN is well-suited for studies of the quality of care for cancer patients, survivorship, and long-term outcomes.
Staphylococcal Pyopericardium Treated with Penicillin
Authors: H. B. Norman, R. M. Ainsworth
Journal: BMJ (1945)

In a series of 185 cases of gas gangrene in the C.M.F. reported on Army Form I 1241 the case-fatality rate has been examined in relation to the treatment given.The combined method of treatment with surgical measures, intravenous antitoxin, and bacteriostatic drugs, when given as recommended, was highly effective in reducing the death rate in cases with gas gangrene of the leg or arm.The death rate in cases of gangrene of the thigh, buttock, or shoulder region was approximately 40% in spite of such treatment, even among those who received penicillin systemically.The findings suggest that the specific treatment was generally effective in controlling the clostridial infection, but that in cases in which surgical excision of the affected tissue is limited in extent some factor associated with the local damage to muscle may be contributing to the severity of the disease.Thanks are due to the Director-General, A.M.S., for access to the reports.I am also indebted to Dr. E.
JAMA Diagnostic Test Interpretation
Authors: Edward H. Livingston, Mary McGrae McDermott
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gadolinium Decreases Stretch-Induced Vulnerability to Atrial Fibrillation
Authors: Frank Bode, Alexander Katchman, Raymond L. Woosley, Michael R. Franz
Journal: Circulation (2000)

Background —Atrial fibrillation (AF) is frequently associated with atrial dilatation caused by pressure or volume overload. Stretch-activated channels (SACs) have been found in myocardial cells and may promote AF in dilated atria. To prove this hypothesis, we investigated the effect of the SAC blocker gadolinium (Gd 3+ ) on AF propensity in the isolated rabbit heart during atrial stretch. Methods and Results —In 16 isolated Langendorff-perfused rabbit hearts, the interatrial septum was perforated to equalize biatrial pressures. Caval and pulmonary veins were occluded. Intra-atrial pressure (IAP) was increased in steps of 2 to 3 cm H 2 O by increasing the pulmonary outflow fluid column. Vulnerability to AF was evaluated by 15-second burst pacing at each IAP level. At baseline, IAP needed to be raised to 8.8±0.2 cm H 2 O (mean±SEM) to induce AF. A dose-dependent decrease in AF vulnerability was observed after Gd 3+ 12.5, 25, and 50 μmol/L was added. AF threshold increased to 19.0±0.5 cm H 2 O with Gd 3+ 50 μmol/L ( P &lt;0.001 versus baseline). Spontaneous runs of AF occurred in 5 hearts on a rise of IAP to 13.8±3.3 cm H 2 O at baseline but never during Gd 3+ . Atrial effective refractory period shortened progressively from 78±3 ms at 0.5 cm H 2 O to 52±3 ms at 20 cm H 2 O ( P &lt;0.05). Gd 3+ 50 μmol/L had no significant effect on effective refractory period. Conclusions —Acute atrial stretch significantly enhances the vulnerability to AF. Gd 3+ reduces the stretch-induced vulnerability to AF in a dose-dependent manner. Block of SAC might represent a novel antiarrhythmic approach to AF under conditions of elevated atrial pressure or volume.
ULCERATIVE BRONCHITIS DUE TO VINCENT'S ORGANISMS
Authors: Chevalier Jackson
Journal: JAMA (1924)

Two cases of pseudomembranous bronchitis due to Vincent's organisms have been observed in the Bronchoscopic Clinic: <h3>Case 1.</h3> —A woman, aged 18, was referred to the clinic by Dr. G. W. Morris, with the history that he had been called to see the patient, who was supposed to have a diphtheria with the membrane persisting and spreading for nearly a month. The tonsils at that time were ulcerated and covered with a whitish membrane. He made a tentative diagnosis of Vincent's angina, which was subsequently verified by laboratory examination, both the bacillus and the spirillum being present in abundance. No diphtheritic organisms were found. Under local applications of tincture of iodin, silver nitrate and some other agents, the faucial lesions completely disappeared in a few weeks. The patient did not recover good health, however, the temperature rising every day, some days as high as 101 F. A mild leukemia was
Abstract B3: CD39+ cancer cells mediate immunosuppression reverted by CD39-blocking antibodies.
Authors: Anne Regairaz, Caroline Laheurte, Nathalie Bonnefoy, Jean-Francois Eliaou, Gilles Alberici, Armand Bensussan, Jeremy Bastid
Journal: Cancer Research (2013)

Abstract The CD39 and CD73 ectonucleotidases hydrolyze extracellular ATP and ADP into immunosuppressive adenosine that binds adenosine receptor and inhibits T cell and NK cell responses. It has been demonstrated that CD39+ Tregs are increased in some human cancers and participate to immunosuppression. The importance of CD39+ Tregs in promoting tumor growth and metastasis has been evidenced in several models in vivo (for a review, see Bastid J et al., Oncogene, 2012). Here, we addressed whether CD39 is expressed by tumor cells and whether CD39+ tumor cells mediate suppression through the CD39-adenosine pathway. Immunohistochemical staining of normal and tumor tissues revealed that CD39 is upregulated in several types of human cancer. In cancer specimens, CD39 is expressed by infiltrating lymphocytes, tumor stroma and tumor cells, whereas its expression in normal samples is absent or weak and mostly limited to vascular endothelia. The expression of CD39 at the cell surface of tumor cells was further directly demonstrated by flow cytometry in human cancer cell lines. We evidenced that CD39+ tumor cells express functional CD39 and inhibit CD4 and CD8 T cell function in a CD39-dependant manner. Treatment with CD39-blocking antibodies was able to alleviate CD39+ tumor cell-mediated inhibition of CD4 and CD8 T cells in co-culture experiments. In conclusion, interfering with the CD39-adenosine pathway could represent a novel immunotherapy strategy for inhibiting Treg and tumor cell-mediated immunosuppression. Furthermore, these results support the ongoing development of CD39-blocking monoclonal antibodies as potential anticancer drugs. Citation Format: Anne Regairaz, Caroline Laheurte, Nathalie Bonnefoy, Jean-Francois Eliaou, Gilles Alberici, Armand Bensussan, Jeremy Bastid. CD39+ cancer cells mediate immunosuppression reverted by CD39-blocking antibodies. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology: Multidisciplinary Science Driving Basic and Clinical Advances; Dec 2-5, 2012; Miami, FL. Philadelphia (PA): AACR; Cancer Res 2013;73(1 Suppl):Abstract nr B3.